Re-Defining Response Monitoring: Where are we Today to Accurately Predict Prognosis and How Does LBx Utility Differ Between Different Cancers?
Time: 9:30 am
• The landscape is changing very quickly, with more entrants into the industry and increasingly promising data being announced on a regular basis
• As non-invasive testing comes to fruition, it’s important we recognise how the industry is evolving and identifying where liquid biopsy can permit the more comprehensive study of disease resulting in patient benefit and healthcare savings
• In NSCLC alone, there are increasing ways liquid biopsies are being applied to further our understanding of disease, with potential to see better treatments reach patients – Most recent progress and research in this area will be shared